AAV2 vector optimization for retinal ganglion cell-targeted delivery of therapeutic genes.
Level 5 - mechanism / opinion, no new human data
Preclinical vector engineering and animal model study with no human clinical data.
PubMed 38200264 · doi:10.1038/s41434-023-00436-8
What was done
Researchers engineered and tested recombinant AAV2 vector variants to improve targeted gene delivery to retinal ganglion cells (RGCs). They evaluated promoter combinations (including CMV enhancer/CBA and human gamma-synuclein [hSNCG] promoters) paired with regulatory elements (WPRE and SV40 intron) via intravitreal delivery. The optimized vector was then used to deliver a 2.2-kb therapeutic transgene, human SIRT1 (hSIRT1), and evaluated for RGC transduction selectivity and neuroprotection in an optic nerve crush model.
What was found
The abstract provides no quantitative figures or statistical values. It reports qualitatively that an AAV2 construct containing the hSNCG promoter, WPRE, a leading CMV enhancer, and an SV40 intron achieved strong, widespread, and selective transduction in RGCs. Delivering hSIRT1 via this vector resulted in robust RGC-selective expression and increased RGC survival after optic nerve crush injury.
Why it matters
Targeted and efficient gene expression in RGCs is a central challenge in developing gene therapies for optic neuropathies such as glaucoma. Optimizing vector backbones with cell-selective promoters and post-transcriptional elements can reduce off-target expression while accommodating moderately sized therapeutic payloads.
Limits
The abstract lacks all quantitative data, sample sizes, effect sizes, and specific animal species details. Because the findings are restricted to preclinical animal models (optic nerve crush), translational efficacy, long-term safety, immune responses to the vector, and durability in human clinical optic neuropathies remain unmeasured.
Cited by
- supports Adeno-associated virus serotype 2 (AAV2) is used as a gene delivery vehicle to target nerve cells at the back of the retina.